0
Sign In  | Subscribe
20 March 2001, Vol 134, No. 6>
Summaries for Patients | 20 March 2001

The Cost-Effectiveness of Testing HIV for Genetic Signs of Drug Resistance as a Guide to the Choice of Therapy FREE

[+] Article and Author Information

The summary below is from the full report titled “Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness.” It is in the 20 March 2001 issue of Annals of Internal Medicine (volume 134, pages 440-450). The authors are MC Weinstein, SJ Goldie, E Losina, CJ Cohen, JD Baxter, H Zhang, AD Kimmel, and KA Freedberg.


Ann Intern Med. 2001;134(6):S89-. doi:10.7326/0003-4819-134-6-200103200-00004
Text Size: A A A

What is the problem and what is known about it so far?

Human immunodeficiency virus (HIV) interferes with the ability to fight infections. Therapy with combinations of anti-HIV drugs can reduce the amount of the virus in the blood and improve patient outcomes. Unfortunately, the virus can become resistant to the drugs, and the patient must then change to another combination. It is now possible to test the genes of the virus directly for signs of resistance to particular drugs (genotypic resistance testing). It is unknown whether the cost of these tests is worth the benefit.

Why did the researchers do this particular study?

To learn whether using genotypic resistance testing to guide the choice of anti-HIV drugs is worth the benefit.

Who was studied?

The researchers used computers to simulate what would happen to a hypothetical “virtual” group of patients with HIV infection.

How was the study done?

Using published data from previous studies, the researchers estimated the effect of using genotypic resistance testing in addition to doctors' judgment to guide the choice of anti-HIV drugs. They looked at 1) patients beginning anti-HIV drugs for the first time [primary resistance testing] and 2) patients in whom the first anti-HIV drug regimen had failed (secondary resistance testing). The researchers then explored what would happen over time depending on whether genotypic resistance testing was used, and they calculated how much each strategy would cost society for a given amount of benefit. Benefit was measured in quality-adjusted life-years (QALYs), a unit of measure that considers not only how long a person lives but also his or her quality of life during that time.

What did the researchers find?

If only about 4 of every 100 patients beginning their first anti-HIV drugs were infected with resistant virus, primary genotypic resistance testing would cost $69,000 per QALY gained. If 20 of every 100 had resistant virus, then primary resistance testing would cost $22,300 per QALY gained. Secondary resistance testing was estimated to cost about $17,000 per QALY gained. On the basis of these findings, and compared with many other accepted therapies, genotypic resistance testing can be considered cost-effective.

What were the limitations of the study?

This study was a computer simulation, so we cannot be sure what the results would be with actual patients.

What are the implications of the study?

Genotypic resistance testing of patients in whom an anti-HIV drug regimen has failed appears to be cost-effective. Genotypic resistance testing of patients beginning their first anti-HIV drug regimen may be cost-effective if the suspicion of resistance is high.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy This Article

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Advertisement

Related Content

Customize your page view by dragging & repositioning the boxes below.

In the Clinic
Management of Newly Diagnosed HIV Infection
Ann Intern Med. 2011;155(7):ITC4-1.
Topic Collections
PubMed Articles
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.
The Lancet infectious diseases Issue date: 2013 Apr
Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.
PLoS medicine Issue date: 2012

Annals of Internal Medicine

Other Resources

Copyright © 2013 The American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Buy This Article

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)